HONG KONG, Feb. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the...
Hence then, the article about akeso receives fifth breakthrough therapy designation from nmpa for ivonescimab in first line treatment of advanced biliary tract cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer )
Also on site :
- Hi3D V1.0 se vuelve de código abierto: el primer modelo 3D de IA de código abierto validado para producción
- Box Office: ‘Clayface’ Lands at No. 1 with $10.4 Million Debut, ‘You Can See Everything’ Adds $6.14 Million on Friday
- 100 Years Ago Today, Harry Houdini Took the Stage With a 104-Degree Fever, and It Was the Last Show He Ever Performed